SBMS-OAGB-JIAI-001
A Study Protocol for Multivariable Regression and Explainable Artificial Intelligence to Support Biliopancreatic Limb Selection in One-Anastomosis Gastric Bypass Using J-I Fat Coverage, Total Small-Bowel Length, and AII
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: 18–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 120 чел. во всех странах исследования.
- Плановое окончание — 11.2029.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 7
Критерии включения
- Adults aged 18 years or older at the time of consent.
- Patients who meet the institution's independent clinical criteria for primary one-anastomosis gastric bypass.
- Planned laparoscopic or robot-assisted OAGB at a participating centre.
- Ability to undergo standardized intraoperative measurement of the J-I segment, P\_JI components, and total small-bowel length when clinically and ethically appropriate.
- Ability to provide informed consent according to local requirements.
- Willingness and reasonable ability to complete the prespecified postoperative follow-up.
Критерии невключения
- Revisional, conversion, or non-primary gastric bypass surgery.
- Operative anatomy that prevents reliable identification or measurement of the ligament of Treitz, the J-I segment, or the ileocecal junction.
- Unaddressed altered gastrointestinal anatomy that is outside the development protocol.
- Severe pre-existing malnutrition or another condition for which experimental variation in BPL length would be considered clinically inappropriate by the treating team.
- Inability to provide informed consent when consent is required.
- Inability to complete the minimum follow-up required by the approved protocol, unless the participant is retained for an approved missing-data or safety analysis.
- Any intraoperative or postoperative circumstance in which the treating surgeon determines that protocol measurement would create unacceptable risk.
Источник: ClinicalTrials.gov, NCT07818317 · запись обновлена в реестре 14 сентября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 8
- Percent total weight loss at 12 months after OAGB — 12 months after OAGB
- Incremental out-of-sample predictive contribution of P_JI for 12-month percent total weight loss — From model development through external validation; primary clinical endpoint assessed at 12 months after OAGB
Цель исследования
This prospective observational cohort study will develop and externally validate a human-supervised, explainable artificial-intelligence decision-support model for analysing factors associated with biliopancreatic limb length selection during one-anastomosis gastric bypass (OAGB). The study will record three prespecified factors: the percentage of the laparoscopic instrument segment J-I covered by visceral or omental fat (P\_JI = 100 × FI/JI), the measured total small-bowel length (TSBL), and the abdominal integral index (AII = (CD/AC) + (CG/EG) + (JI/FI)). The study will evaluate weight-loss effectiveness, nutritional and malabsorptive outcomes, bile/acid reflux, major complications, and technical feasibility. During model development, the AI system will not autonomously assign a BPL length. The operating bariatric surgeon will make the clinical decision, and the model will be evaluated for calibration, external validity, factor contribution, safety constraints, and abstention.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07818317 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.